PMID- 9590657
OWN - NLM
STAT- MEDLINE
DCOM- 19980603
LR  - 20061115
IS  - 0301-472X (Print)
IS  - 0301-472X (Linking)
VI  - 26
IP  - 5
DP  - 1998 May
TI  - Allogeneic bone marrow or peripheral blood cell transplants in adults with 
      hematologic malignancies: a single-center experience.
PG  - 409-14
AB  - This is a retrospective study of 97 patients who received either allogeneic bone 
      marrow transplant (BMT) (n=52) or peripheral blood cell transplant (PBCT) (n=45) 
      at our institution from human leukocyte antigen (HLA)-identical sibling donors 
      between January 1994 and January 1997. The two groups were comparable with 
      respect to diagnosis, age, sex, interval from diagnosis, and disease phase. They 
      were prepared with cyclophosphamide (CY) and fractionated total-body irradiation 
      (TBI) (n=51) or CY and thiotepa (n=46). Graft-vs.-host disease (GVHD) prophylaxis 
      consisted of cyclosporin A and methotrexate. Patients who received PBCT exhibited 
      faster neutrophil engraftment (day 14 vs. day 16, p = 0.002) than those in the 
      BMT group, as well as higher platelet counts on day 20 (32x10(9)/kg vs. 
      21x10(9)/kg, p = 0.001), but graft function as assessed by platelet counts on 
      days 50, 100, and thereafter was comparable. The number of days spent in the 
      hospital, days on intravenous antibiotics, and days of fever were lower in the 
      PBCT group, but not significantly. Acute GVHD, chronic GVHD, and cytomegalovirus 
      infections were comparable between the two groups. The overall actuarial 3-year 
      transplant-related mortality (TRM) rate for BMT vs. PBCT patients was 20 vs. 33% 
      (p = 0.1), the survival rate was 53 vs. 48% (p = 0.3), and the relapse rate was 
      42 vs. 43% (p = 0.8). For patients in first complete remission, these figures 
      were TRM 12 vs. 22% (p = 0.2), survival rate 75 vs. 70% (p = 0.4) and relapse 
      rate 31 vs. 9% (p = 0.4), respectively, for the BMT and PBCT groups. These data 
      suggest that the short-term outcome of allogeneic PBCT is not significantly 
      different from that of allogeneic BMT in patients with hematologic malignancies. 
      Long-term results are not available at present.
FAU - Bacigalupo, A
AU  - Bacigalupo A
AD  - Divisione Ematologia II, Ospedale San Martino, Genoa, Italy.
FAU - Zikos, P
AU  - Zikos P
FAU - Van Lint, M T
AU  - Van Lint MT
FAU - Valbonesi, M
AU  - Valbonesi M
FAU - Lamparelli, T
AU  - Lamparelli T
FAU - Gualandi, F
AU  - Gualandi F
FAU - Occhini, D
AU  - Occhini D
FAU - Mordini, N
AU  - Mordini N
FAU - Bregante, S
AU  - Bregante S
FAU - Berisso, G
AU  - Berisso G
FAU - Vitale, V
AU  - Vitale V
FAU - Sessarego, M
AU  - Sessarego M
FAU - Marmont, A M
AU  - Marmont AM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Antigens, Viral)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, Viral/blood
MH  - *Bone Marrow Transplantation/adverse effects/mortality
MH  - Cause of Death
MH  - Child
MH  - Child, Preschool
MH  - Cytomegalovirus/immunology
MH  - Cytomegalovirus Infections/etiology
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Hematologic Neoplasms/*therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 1998/05/20 00:00
MHDA- 1998/05/20 00:01
CRDT- 1998/05/20 00:00
PHST- 1998/05/20 00:00 [pubmed]
PHST- 1998/05/20 00:01 [medline]
PHST- 1998/05/20 00:00 [entrez]
PST - ppublish
SO  - Exp Hematol. 1998 May;26(5):409-14.